Affinity of company of biology medicine science and technology announces to finish Pre-A annulus financing, financing forehead amounts to 60 million yuan, get cast capital of Fang Weipan continuous heavy rain, with deliver Fang Weiteng far fund.
Affinity is small environment of a tumour is answered model business of medicaments research and development, devote oneself to the patent with low efficient poison to fight the development of cancerous new drug and production. Use certain protein enzymatic the characteristic that organizes particularity tall expression in tumor, the medicaments that development activations in tumor small environment is transmissive system. Through be being transformed to the design of medicaments, make its are activationed by particularity in tumor organization, reduce disease of its systematization noxiousness to widen its treat the window thereby.
Company CEO holds doctor of time of Liu of official of chief scientist, medicine concurrently to think, intelligence turns the tide that medicaments is international consensus, medical tycoon also is in layout this domain. It is one of efficient ways that raise tumor to treat the effect, market prospect is capacious. Liu Chen still expresses, PD-1 domain has appeared a large number of players, competition is very intense, begin to depreciate even competition. Affinity is dedicated do PD-1 to treat associate jointly, change medicaments platform to undertake reforming with intelligence, the help improves the transponder reply efficiency of PD-1, extend get used to disease.
It is reported, liu Chen ever held the post of immunity of American Scripps institute to fasten a professor, the research experience that has more than 20 years of immunology and mechanism of medicaments design core.
